Cell Therapy Manufacturing Automation Market Forecast Report: Size, Share, and Opportunities 2030

 What Is the Predicted Market Size and CAGR of the Cell Therapy Manufacturing Automation Market by the End of the 2030?

 The cell therapy manufacturing market size has grown rapidly in recent years. It will grow from $1.81 billion in 2025 to $2.08 billion in 2026 at a compound annual growth rate (CAGR) of 14.8%. The growth in the historic period can be attributed to increasing cell-processing demand, growing manufacturing scalability needs, rising adoption of automated bioreactors, expansion of GMP-compliant workflows, and increasing focus on production consistency.

 
 The cell therapy manufacturing market size is expected to see rapid growth in the next few years. It will grow to $3.58 billion in 2030 at a compound annual growth rate (CAGR) of 14.5%. The growth in the forecast period can be attributed to increasing personalized-therapy volumes, growing investment in automation platforms, rising need for contamination-free workflows, expansion of large-scale commercial manufacturing, and increasing regulatory-driven quality requirements. Major trends in the forecast period include technology advancements in closed systems, automation-driven process innovations, integrated workflow developments, real-time analytics research, and advanced robotics research and development.
 
 Get your free report sample today:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=30551&type=smp
 
 What Are the Major Growth Drivers for the Cell Therapy Manufacturing Automation Market?
 The growing demand for gene therapies is expected to propel the growth of the cell therapy manufacturing automation market going forward. Gene therapy refers to a medical technique that involves modifying or replacing defective genes to treat or prevent diseases. The increasing demand for gene therapy is due to advancements in genetic sequencing and diagnostics, which enable precise identification of disease-causing genes for targeted treatment. Cell therapy manufacturing automation supports gene therapy by streamlining and standardizing complex production processes to ensure consistent quality and scalability. It enhances therapeutic development by reducing errors, improving efficiency, and enabling reliable large-scale manufacturing of gene-modified cells. For instance, in December 2024, according to the American Society of Gene & Cell Therapy (ASGCT), a US-based non-profit medical and scientific organization, the Food and Drug Administration (FDA) approved six gene therapy products in 2023, up from five approvals in 2022. Therefore, the growing demand for gene therapies is driving the growth of the cell therapy manufacturing automation market.
 
 What Are the Primary Market Segments in the Cell Therapy Manufacturing Automation Market?
 The cell therapy manufacturing automation market covered in this report is segmented — 
 
 1) By Component: Hardware, Software, Services
 2) By Cell Type: T-Cells, Stem Cells, Natural Killer (NK) Cells, Other Cell Types
 3) By Process: Upstream Processing, Downstream Processing, Fill-Finish, Quality Control, Other Processes
 4) By End-User: Pharmaceutical And Biotechnology Companies, Research Institutes, Contract Manufacturing Organizations (CMOs), Other End-Users
 
 Subsegments:
 1) By Hardware: Automated Bioreactor Systems, Robotic Handling Platforms, Automated Separation Devices, Automated Expansion Units, In Line Quality Analyzers
 2) By Software: Electronic Batch Record Software, Manufacturing Execution Software, Workflow Management Software, Data Monitoring Software, Compliance Management Software
 3) By Services: Installation Services, Maintenance Services, Validation Services, Training Services, Technical Support Services
 
 Which Future-Ready Trends Are Expected to Influence the Cell Therapy Manufacturing Automation Market?
 Major companies operating in the cell therapy manufacturing automation market are focusing on developing advanced solutions, such as automated cell therapy system, to connect multi-stage manufacturing workflows into unified, validated digital frameworks that reduce manual touchpoints and support regulatory compliance. An automated cell therapy system refers to an off-the-shelf validated automation solution that digitally connects cell therapy instruments (e.g., magnetic separation, centrifugation, electroporation, incubators) into a single interface, enabling traceability, repeatability, and cGMP compliance across production stages. For instance, in January 2024, Thermo Fisher Scientific Inc., a US-based life sciences company, launched Gibco CTS Cellmation Software, a first-of-its-kind automation solution. It is a first-of-its-kind, off-the-shelf validated software solution that digitally connects instruments from across Thermo Fisher’s cell therapy portfolio to automate manufacturing workflows. It includes a pre-validated automation system powered by Emerson’s DeltaV technology, enabling seamless integration and control of multiple instruments without costly custom projects, and it establishes traceable, repeatable workflows that help ensure compliance with cGMP and data security regulations, reducing manual touchpoints for ground therapy developers.
 
 Who Are the Top Performers and Innovators in the Cell Therapy Manufacturing Automation Market?
 Major companies operating in the cell therapy manufacturing automation market are Thermo Fisher Scientific Inc., Merck KGaA, Fujifilm Holdings Corporation, Corning Incorporated, Lonza Group AG, Cytiva, WuXi AppTecCo. Ltd., Hitachi High Technologies Corp., CatalentInc., Sartorius AG, Beckman Coulter Life Sciences, Terumo BCT Inc., Miltenyi Biotec, Oxford Biomedica Plc, National Resilience LLC, Minaris Regenerative Medicine LLC, Tulip Interfaces Inc., Invetech Pty Ltd., BlueRock Therapeutics LLC, Cellares Inc., Ascential Medical & Life Sciences, Cell and Gene Therapy Catapult 
 
 Get the detailed cell therapy manufacturing automation market report today
 https://www.thebusinessresearchcompany.com/report/cell-therapy-manufacturing-automation-market-report
 
 Which Regional Markets Are Likely to See the Most Significant Expansion in the Coming Years?
 North America was the largest region in the cell therapy manufacturing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell therapy manufacturing automation market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
 
 Contact Us:
 
 The Business Research Company: https://thebusinessresearchcompany.com/ 
 Americas +1 310–496–7795
 Asia +44 7882 955267 & +91 8897263534
 Europe +44 7882 955267 
 Email: info@tbrc.info 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company